How can we help your research?
Genoskin keeps real, donor-consented human skin alive and functional for 7 days, so your teams generate reliable human data before clinical trials.
Pharmaceutical R&D
De-risk drug development with human skin data. Support candidate selection, toxicity, and translational decisions. Replace animal models with human data.
Explore →
Biotechnology
Validate your pipeline with flexible ex vivo skin platforms. Access custom study designs for emerging therapeutics. Get reliable human data at every stage.
Explore →
Cosmetics & Beauty
Substantiate safety, efficacy, and product claims. Use human skin data that regulators and consumers trust. Replace in vitro with real tissue.
Explore →
Medical Devices
Assess biocompatibility and local skin tolerance. Test with human tissue reflecting real-world response. Meet regulatory requirements with confidence.
Explore →
Academic & Research
Access well-characterized ex vivo skin models. Leverage expert services for discovery and validation. Generate publication-ready data with human tissue.
Explore →Expert-designed studies and research-ready products for every need
ImmunoSafe: ISR Platform®
Predict injection-site reactions before first-in-human.
Uses live, immunocompetent HypoSkin® to characterise mast cell-dependent and independent inflammatory responses to subcutaneous and intradermal biologics. AUDACY bioinformatics delivers actionable first-in-human data.
Local Tolerance Studies
Test injectables, devices, and topicals on real human skin.
Assess inflammatory responses to subcutaneous, transdermal, and intradermal vaccines, therapeutics, and medical devices using HypoSkin® — containing real human epidermis, dermis, adipose tissue, and all native immune cells. Delivered as a full report with actionable insights.
VaxSkin® Platform
Characterise immune response at the injection site.
Multiplex cytokine release assays combined with proprietary AUDACY bioinformatics differentiate vaccine-driven from adjuvant-driven immune activation. Published with the mRNA-1273 COVID-19 vaccine in the journal Allergy.
Topical & Transdermal Efficacy
Substantiate claims with human-relevant data.
High-caliber non-clinical services using live human skin models and expert analytical tools to solidify product efficacy claims. From cosmetic claim substantiation to transdermal drug delivery — all backed by publication-ready data.
InflammaSkin® Platform
Accelerate inflammatory disease research with human data.
InflammaSkin® is the most relevant ex vivo model for inflammatory skin conditions. Supports psoriasis, Type-2 barrier impairment, and wound healing research with robust, publication-ready human data that replaces animal models.
E-shop · 3 clicks from your lab
Order ready-to-use ex vivo skin and primary mast cells.
Shipped globally with full protocols, scientific support, and the option to speak to a Genoskin scientist before you buy. Order today, receive viable human skin in your lab within [X] business days.
Don’t see your industry or study type? Tell us about your research →
The benchmark in human skin science
“
“What is needed in order to reduce the failure rate of novel drugs in clinical development are techniques that provide a better insight in PK and PD processes in clinical trials such as the dOFM and the use of human tissue as provided by Genoskin.”
“
“This study underscores the power of combining new approach methodologies, such as our advanced viable human skin model, and advanced bioanalytics with innovative biologics. The data generated here provide a strong foundation for this exciting testing platform and continued clinical advancement of MTX-001.”
“
The results confirm and build upon previous reported results from ex-vivo studies done with human skin specimens conducted by Genoskin.
Two ways to work with us
Custom CRO services or self-serve skin models. Both backed by the same science.
Frequently asked questions
How does ex vivo human skin differ from reconstructed skin models, and why does it matter for non-clinical studies?
Is ex vivo human skin accepted for IND submissions under the FDA Modernization Act 2.0?
How reproducible are Genoskin's results given that models come from different human donors?
How long is ex vivo human skin viable, and what's the typical turnaround time for a Genoskin study?
Genoskin’s patented biostabilization technology keeps ex vivo human skin alive and immunocompetent for up to 7 days post-excision, which is sufficient for the vast majority of safety, tolerability, and multi-timepoint dose-response studies. For custom CRO studies, most projects kick off within 2 weeks of contract signature and are completed within 4 to 8 weeks from initiation to final report. E-shop orders ship globally and arrive viable at your lab within [X] business days. [VERIFY shipping timelines]
Where does Genoskin ship, and is the skin ethically sourced?
Genoskin ships ex vivo skin models globally from laboratories in Toulouse, France and Salem, Massachusetts, serving customers across North America, Europe, Asia-Pacific, and beyond. Every model comes from skin donated by patients undergoing elective surgery, given freely with full informed consent through our partner hospital network in France and the United States. No skin is purchased and participation is never incentivized. Every sample is fully traceable, approved by independent ethics committees, and handled under strict donor confidentiality protocols.
Have more questions? Visit our FAQ page →
From donated skin to reliable human data
Step 1
Ethically sourced
Human skin from consented surgical donations, processed within hours. Every sample is ethically sourced.
Step 2
Biostabilized
Patented technology keeps tissue alive and immunocompetent for up to 7 days, with 14 immune cell types naturally preserved.
Step 3
Human-relevant data
Translational endpoints: histology, multiplex cytokine analysis, spatial biology, flow cytometry, and bioinformatics.
Real and alive ex vivo human skin. Immunocompetent for 7 days. The most predictive non-clinical model available today.
Ex vivo human skin vs. reconstructed skin vs. animal models
The most predictive non-clinical model depends on what you’re testing. Here’s how Genoskin’s ex vivo human skin compares.
| Feature | Genoskin — Ex vivo human skin | Reconstructed Skin | Animal Models |
|---|---|---|---|
| All native cell types | ✓Full immune compartment | ✗Keratinocytes only, no immune cells | ✗0 human immune cells, cross-species gap |
| Human-relevant data | ✓Direct clinical translation | ~Partial | ✗Non-human biology, poor translation |
| Full skin layers | ✓Epidermis + dermis + hypodermis | ✗Epidermis only | ~All layers, but anatomically different |
| Skin appendages | ✓Hair follicles, sweat glands preserved | ✗None | ~Different structure |
| Immune response profiling | ✓Spatial biology + multiomics | ✗No immune cells | ✗Reduced translational relevance |
| Ethical sourcing | ✓Consented human donation | ~Human-derived cells, varying consent rigor | ✗Animal use required |
| NAMs regulatory direction | ✓Aligned with FDA & EMA frameworks | ~Limited context of use | ~Reduced regulatory preference post-FDA Modernization Act 2.0 |
About Genoskin
Human Skin. Real answers.
Founded in Toulouse in 2011 by Dr. Pascal Descargues (PhD, CNRS), Genoskin pioneered the world’s first biostabilized ex vivo human skin platform, a breakthrough that finally bridges the gap between lab models and clinical reality. We’ve since expanded our technology with HypoSkin®, the only injectable ex vivo model incorporating the hypodermis, and have rigorously characterized immunocompetency across both platforms.
Today, from our labs in Toulouse and Salem, MA, we partner with 500+ customers across pharma, biotech, vaccines, cosmetics, and academic research, helping them make better decisions, faster, with human skin that behaves like human skin.
Fresh from the lab: webinars, insights, and publications, updated regularly.
On-demand webinars from Genoskin scientists and industry experts
In-depth articles, application notes, and scientific explainers, updated regularly
Scientific conferences, posters, and events where you’ll find our team
Application notes, protocols, and resources for your research
Latest news, partnerships, and announcements from Genoskin
